Curcumin - Seer Pharmaceuticals

Drug Profile

Curcumin - Seer Pharmaceuticals

Latest Information Update: 15 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seer Pharmaceuticals
  • Developer Cystic Fibrosis Foundation Therapeutics; Seer Pharmaceuticals
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 26 Sep 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top